Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.48
CYTX's Cash to Debt is ranked higher than
53% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 68.42 vs. CYTX: 0.48 )
CYTX' s 10-Year Cash to Debt Range
Min: 0.39   Max: No Debt
Current: 0.48

Equity to Asset 0.03
CYTX's Equity to Asset is ranked higher than
50% of the 751 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CYTX: 0.03 )
CYTX' s 10-Year Equity to Asset Range
Min: -0.83   Max: 0.94
Current: 0.03

-0.83
0.94
F-Score: 2
Z-Score: -12.07
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -251.55
CYTX's Operating margin (%) is ranked higher than
63% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -68.50 vs. CYTX: -251.55 )
CYTX' s 10-Year Operating margin (%) Range
Min: -657.27   Max: -68.58
Current: -251.55

-657.27
-68.58
Net-margin (%) -214.64
CYTX's Net-margin (%) is ranked higher than
64% of the 794 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CYTX: -214.64 )
CYTX' s 10-Year Net-margin (%) Range
Min: -663.34   Max: -30.65
Current: -214.64

-663.34
-30.65
ROE (%) -835.79
CYTX's ROE (%) is ranked lower than
52% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. CYTX: -835.79 )
CYTX' s 10-Year ROE (%) Range
Min: -1935.19   Max: -16.29
Current: -835.79

-1935.19
-16.29
ROA (%) -62.24
CYTX's ROA (%) is ranked higher than
57% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -17.51 vs. CYTX: -62.24 )
CYTX' s 10-Year ROA (%) Range
Min: -204.9   Max: -8.21
Current: -62.24

-204.9
-8.21
ROC (Joel Greenblatt) (%) -2910.72
CYTX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 876 Companies
in the Global Biotechnology industry.

( Industry Median: -201.33 vs. CYTX: -2910.72 )
CYTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2910.72   Max: -155.49
Current: -2910.72

-2910.72
-155.49
Revenue Growth (%) -7.80
CYTX's Revenue Growth (%) is ranked higher than
71% of the 638 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CYTX: -7.80 )
CYTX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 13.3
Current: -7.8

0
13.3
EBITDA Growth (%) -16.40
CYTX's EBITDA Growth (%) is ranked higher than
68% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. CYTX: -16.40 )
CYTX' s 10-Year EBITDA Growth (%) Range
Min: -27.3   Max: 37.5
Current: -16.4

-27.3
37.5
EPS Growth (%) -13.40
CYTX's EPS Growth (%) is ranked higher than
73% of the 636 Companies
in the Global Biotechnology industry.

( Industry Median: -12.20 vs. CYTX: -13.40 )
CYTX' s 10-Year EPS Growth (%) Range
Min: -41.5   Max: 102.7
Current: -13.4

-41.5
102.7
» CYTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CYTX Guru Trades in Q3 2013

John Burbank Sold Out
» More
Q4 2013

CYTX Guru Trades in Q4 2013

Paul Tudor Jones 11,026 sh (New)
Jim Simons 46,331 sh (New)
» More
Q1 2014

CYTX Guru Trades in Q1 2014

Paul Tudor Jones 14,433 sh (+30.9%)
Jim Simons Sold Out
» More
Q2 2014

CYTX Guru Trades in Q2 2014

Paul Tudor Jones 14,633 sh (+1.39%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-09-30 Sold Out $2.1 - $2.82 $ 1.37-45%0
John Burbank 2012-12-31 New Buy$2.58 - $4.44 $ 1.37-63%18450
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 130.00
CYTX's P/B is ranked lower than
63% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CYTX: 130.00 )
CYTX' s 10-Year P/B Range
Min: 2.93   Max: 636
Current: 130

2.93
636
P/S 10.00
CYTX's P/S is ranked higher than
58% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 17.18 vs. CYTX: 10.00 )
CYTX' s 10-Year P/S Range
Min: 5.74   Max: 45.29
Current: 10

5.74
45.29
EV-to-EBIT -2.91
CYTX's EV-to-EBIT is ranked higher than
78% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYTX: -2.91 )
CYTX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.91

Current Ratio 1.23
CYTX's Current Ratio is ranked higher than
52% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. CYTX: 1.23 )
CYTX' s 10-Year Current Ratio Range
Min: 1.1   Max: 26.46
Current: 1.23

1.1
26.46
Quick Ratio 0.96
CYTX's Quick Ratio is ranked higher than
52% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CYTX: 0.96 )
CYTX' s 10-Year Quick Ratio Range
Min: 0.96   Max: 24.95
Current: 0.96

0.96
24.95

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.62
CYTX's Price/Median PS Value is ranked higher than
84% of the 961 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. CYTX: 0.62 )
CYTX' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 2.71
Current: 0.62

0.36
2.71
Forward Rate of Return (Yacktman) -53.68
CYTX's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CYTX: -53.68 )
CYTX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -206.8   Max: 38
Current: -53.68

-206.8
38

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:XMPA.Germany
Cytori Therapeutics, Inc. was initially formed as a California general partnership in July 1996, and incorporated in the State of Delaware in May 1997. The Company is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns. Its core product is the Celution System, which extracts the naturally occurring ADRCs from a patient's own fat tissue and is CE Marked for a range of soft tissue procedures, including breast reconstruction. The company has completed three clinical trials using the Celution System for breast reconstruction, pipeline applications acute myocardial infarction, and chronic myocardial ischemia. It is involved in the European ADVANCE trial for acute myocardial infarction; and the U.S. trial for chronic myocardial ischemia. The company also sells StemSource cell banking line, including cell and tissue banking lines, as well as the Puregraft System that optimizes the fat graft preparation process. Its therapeutic areas comprises of cardiovascular disease, specifically refractory heart failure due to chronic myocardial ischemia, and the treatment of thermal burns. Its customers in Japan consist primarily of researchers at academic hospitals and clinics. It also has a network of distributors who offer Celution Systems, instrumentation and consumables and Puregraft System to surgeons and hospitals throughout Europe.
» More Articles for CYTX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: SSP, BMTI, POL, ANAC, CYTX Mar 26 2012 
Weekly CFO Buys Highlight: SSP, HPOL, CYTX, AGYS, VRX, TPI Mar 19 2012 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 09 2010 
Cytori Therapeutics Inc (CYTX) CFO Mark E Saad buys 6,000 Shares May 21 2010 
cooldecency99 note on CYTX May 01 2010 
creiter note on CYTX Jan 03 2010 
Cytori Therapeutics Inc Reports Operating Results (10-Q) Aug 10 2009 
Cytori Reports 2nd Quarter 2009 Financial Results Aug 10 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 6,600 Shares May 20 2009 
Cytori Therapeutics Inc (CYTX) CEO Christopher J Calhoun buys 3,250 Shares May 19 2009 

More From Our Partners
Stocks Hitting 52-Week Lows Aug 22 2014 - BENZINGA

More From Other Websites
CYTORI THERAPEUTICS, INC. Financials Aug 19 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Aug 19 2014
BARDA Executes Contract Option with Cytori for Continued Development of Thermal Burn Injury Counter... Aug 19 2014
Cytori Appoints a New Vice President of Finance and Chief Financial Officer Aug 18 2014
Cytori Cell Therapy Reduces Hand Disability and Pain in Scleroderma Patients Aug 12 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change... Aug 11 2014
Cytori Reports Second Quarter 2014 Business and Financial Results Aug 11 2014
Principal Investigator Of Suspended Cytori Stem Cell Trials Remains Hopeful Aug 06 2014
Ascendiant Downgrades Cytori Therapeutics As ATHENA Trials Are Put On Hold Aug 06 2014
[$$] Cytori Halts Athena Trials Over Safety Concerns Aug 05 2014
Cytori halts stem cell study due to adverse events Aug 05 2014
Cytori halts stem cell study due to adverse events Aug 05 2014
Cytori suspends enrollment in cell therapy trials Aug 05 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 05 2014
Cytori Provides Update on ATHENA Trial Status Aug 05 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Aug 04 2014
Cytori to Webcast Second Quarter Financial Results on August 11 Aug 04 2014
Cytori Technology Selected for NHLBI Funded Trial in LVAD Patients Jul 22 2014
CYTORI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jul 21 2014
Cytori Receives Notice of Intent to Exercise First Contract Option from BARDA Jul 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide